文献速递消化内镜消化道肿瘤与早癌

新一代全光谱内镜与标准前视结肠镜的比较:一项多中心、随机、串联结肠镜试验(J-FUSE研究)

New-generation full-spectrum endoscopy versus standard forward-viewing colonoscopy: a multicenter, randomized, tandem colonoscopy trial (J-FUSE Study).
PubMed 文献 · Gastrointest Endosc · 2018-06-13

这项多中心随机串联结肠镜检查试验纳入40至75岁转诊行筛查、监测、粪便隐血阳性或有症状者,比较新一代全光谱内镜(FUSE)与标准前视结肠镜(SFVC)的结直肠腺瘤漏诊率。345例入组、319例纳入符合方案分析,FUSE的每例患者腺瘤漏诊率显著低于SFVC。

要点

  • FUSE每例患者腺瘤漏诊率为11.7%,显著低于SFVC的22.9%(P < .001)。
  • 直径≤5 mm病变的每例患者腺瘤漏诊率FUSE为10.4%,显著低于SFVC的20.0%(P = .0057)。
  • 升结肠的每例患者腺瘤漏诊率FUSE为4.3%,显著低于SFVC的10.6%(P = .0212)。

核心结论

  • FUSE在每例患者腺瘤漏诊率和腺瘤漏诊率两方面均优于SFVC,且对直径≤5 mm病变及升结肠病变,FUSE的每例患者腺瘤漏诊率也显著低于SFVC。

研究设计与样本

  • 多中心、随机、串联结肠镜试验,在8家机构前瞻性纳入40至75岁转诊行筛查、监测、粪便隐血试验阳性或有症状者,采用计算机生成的分层随机化按1:1分组,内镜医师和患者均未设盲。
  • 共入组345例患者,其中319例纳入符合方案分析。

主要发现

  • 每例患者腺瘤漏诊率FUSE为11.7%(95%CI 8.0%-15.4%),SFVC为22.9%(95%CI 17.5%-28.3%),FUSE显著低于SFVC(P < .001)。
  • 直径≤5 mm病变的每例患者腺瘤漏诊率FUSE为10.4%(95%CI 6.5%-14.3%),SFVC为20.0%(95%CI 14.4%-25.6%),FUSE显著低于SFVC(P = .0057)。
  • 升结肠的每例患者腺瘤漏诊率FUSE为4.3%(95%CI 1.4%-7.2%),SFVC为10.6%(95%CI 6.1%-15.1%),FUSE显著低于SFVC(P = .0212)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although colonoscopy is the criterion standard for detection of colorectal adenomas, some adenomas are missed. Full-spectrum endoscopy (FUSE) allows for observation with a 330-degree angle of view, which is expected to decrease the miss rate. However, no consensus has been reached regarding the superiority of FUSE over standard forward-viewing colonoscopy (SFVC) for detection of adenomas; we therefore compared new-generation FUSE and SFVC regarding colorectal adenoma miss rate (AMR) in this, the first reported randomized control trial using new-generation FUSE. METHODS: We enrolled individuals aged 40 to 75 years who had been referred for screening, surveillance, fecal occult blood test positivity, or symptoms in a prospective randomized trial of tandem colonoscopy in 8 institutions. Patients were randomly assigned (1:1) via computer-generated stratified randomization. Neither the endoscopists nor patients were blinded to the allocation. The primary endpoint was AMR per patient (AMR-PP). RESULTS: We enrolled 345 patients and included 319 in the per-protocol analyses. AMR-PP was significantly lower with FUSE (11.7%; 95% confidence interval [CI], 8.0%-15.4%) than with SFVC (22.9%; 95% CI, 17.5%-28.3%; P < .001). AMR-PP for lesions ≤5 mm in size was significantly lower with FUSE (10.4%; 95% CI, 6.5%-14.3%) than with SFVC (20.0%; 95% CI, 14.4%-25.6%; P = .0057). Furthermore, AMR-PP in the ascending colon was significantly lower with FUSE (4.3%; 95% CI, 1.4%-7.2%) than with SFVC (10.6%; 95% CI, 6.1%-15.1%; P = .0212). CONCLUSIONS: FUSE is superior to SFVC regarding both AMR-PP and AMR; additionally, AMR-PP is both significantly lower with FUSE than SFVC for lesions ≤5 mm in size and in the ascending colon. (Clinical trial registration number: UMIN000020448.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Kudo T, Saito Y, Ikematsu H, et al. New-generation full-spectrum endoscopy versus standard forward-viewing colonoscopy: a multicenter, randomized, tandem colonoscopy trial (J-FUSE Study). Gastrointest Endosc. 2018. PMID: 29908178. doi:10.1016/j.gie.2018.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。